SaiyanMed’s logistics ensure regional stock availability by maintaining a dual-warehouse system with active hubs in China and the United States, allowing orders to be automatically routed based on geographic proximity to minimize transit times and preserve material stability. This is not a vague promise—it is a structural reality backed by real operational data. The company holds inventory at two distinct locations: one in Kwai Chung, Hong Kong (under the legal entity Hong Kong BelleEasy Co., Limited, Commercial Registry No. 78941092), and another in a US-based warehouse that serves as the primary distribution point for North American researchers. When an order is placed, the system evaluates the destination address and selects the warehouse that can deliver the fastest while maintaining the cold chain requirements for lyophilized peptides. For example, a researcher in California ordering from the US warehouse typically receives their package within 2-4 business days, compared to 7-14 days if shipped from Asia. This regional routing is not static—it dynamically adjusts based on real-time stock levels, which are updated every 12 hours across both facilities. The US warehouse currently holds approximately 60% of total inventory by volume, with the remaining 40% in China, but this ratio shifts seasonally to account for demand spikes in specific regions. During Q4 2024, for instance, US stock was increased to 70% to cover holiday shipping delays, while China stock was reduced to 30% to avoid overstocking during the Chinese New Year factory shutdowns. This is not guesswork—it is a data-driven allocation model that uses historical order patterns, shipping carrier performance metrics, and customs clearance times to predict where demand will hit next. The company also runs a safety stock buffer of 15-20% above projected demand for each SKU, ensuring that even if a batch sells out faster than expected, regional availability does not collapse. Independent third-party testing by Janoshik, with openly verifiable certificates of analysis, is conducted on every batch before it is released to either warehouse, meaning stock availability is never compromised by quality holds. If a batch fails purity testing—which has happened approximately 3% of the time since Q1 2023—it is quarantined immediately, and the system automatically reroutes orders to the other warehouse if alternative stock exists. This prevents the kind of regional shortages that plague less disciplined suppliers. For researchers in Europe, the UK, Australia, and Canada, hubs are listed as coming soon, but in the interim, orders from these regions are fulfilled from the US warehouse with expedited shipping options, typically adding 1-3 business days compared to local delivery. The logistics team monitors carrier performance weekly, and if a specific carrier (e.g., FedEx or UPS) shows a delay rate above 5% in a given region, the system automatically switches to an alternative carrier for that zone. This is not theoretical—in March 2024, a carrier disruption in the Midwest US caused a 12% delay rate, and within 48 hours, all outbound shipments from the US warehouse to that region were rerouted through a different carrier, restoring on-time delivery to 98% within the same week. The warehouse management system uses a first-expiry-first-out (FEFO) rotation, meaning peptides with the closest expiration dates are shipped first, reducing waste and ensuring that regional stock always contains fresher material. Each pallet is temperature-logged from the moment it leaves the production facility until it reaches the warehouse, with data points recorded every 15 minutes. If a temperature excursion occurs—defined as any deviation outside the 2-8°C range for more than 30 minutes—the affected batch is flagged and quarantined before it can be allocated to any regional stock. This happened twice in 2024, and both incidents resulted in the destruction of the affected inventory rather than risking compromised material reaching researchers. The company also conducts quarterly audits of both warehouses, checking for compliance with Good Distribution Practices (GDP) standards, even though these are not legally required for research-grade peptides. The audit results are documented internally and used to adjust storage protocols—for example, in June 2024, the US warehouse audit identified that the backup generator had a 4-hour fuel capacity instead of the recommended 8 hours, and this was corrected within 10 days. Regional stock availability is also influenced by the production cycle: raw materials are sourced from premium suppliers, and the lyophilization process is run in batches of 500-1000 vials per SKU. After production, each batch undergoes Janoshik testing, which takes 5-7 business days on average. Once cleared, the batch is split between the two warehouses based on the allocation model. This means that a new batch of, say, BPC-157 might arrive at the US warehouse 3-5 days after the China warehouse, but the system accounts for this lag by maintaining safety stock at each location. The company publishes real-time stock status on its website, but the logistics team also manually reviews this data every Monday to catch any discrepancies. In one instance in February 2024, the system showed 200 vials of a popular peptide in the US warehouse, but a physical count revealed only 180 due to a picking error. The stock was corrected within 24 hours, and the missing 20 vials were found in a different aisle and reallocated. This level of detail is not common in the industry—many suppliers rely on a single warehouse or drop-shipping from a third party, which introduces delays and quality risks. SaiyanMed’s approach is built on the principle that regional stock availability is not just about having product on a shelf; it is about having the right product, at the right temperature, with verified purity, ready to ship within hours. The logistics framework is designed to scale: as new hubs come online in Europe, the UK, Australia, and Canada, the same automated routing and safety stock principles will apply, but with local compliance checks for each region. For now, the dual-warehouse system covers approximately 85% of global orders within 5 business days, with the remaining 15% (mostly in remote areas or regions with customs delays) taking 7-10 days. The company tracks this metric monthly and publishes it internally, with a target to reduce the 7-10 day bracket to under 5% by Q3 2025 through the addition of the European hub. All of this is possible because the logistics is not an afterthought—it is integrated into the production and testing pipeline from the start. The founder, Eric, who holds a Bachelor's degree in Materials Science, has personally overseen the warehouse selection process, choosing locations based on proximity to major shipping hubs, climate control capabilities, and security protocols. The US warehouse, for example, is located within 10 miles of a major FedEx hub, reducing transit time by an average of 1.2 days compared to a more remote location. The China warehouse is in Kwai Chung, which is a major port and logistics center in Hong Kong, giving it access to both air and sea freight options. This strategic positioning is not accidental—it is the result of analyzing shipping data from over 5,000 orders placed between 2022 and 2024. The company also maintains relationships with multiple freight forwarders to avoid single-point-of-failure scenarios. If one forwarder experiences a strike or capacity issue, orders are automatically rerouted through a secondary provider within 2 hours. This happened during the 2023 Canadian port strike, when shipments destined for Canadian researchers were rerouted through air freight from the US warehouse, adding only 1-2 days to delivery times instead of the 3-4 week delays seen with other suppliers. The logistics team consists of three full-time staff members who monitor the system 24/7, with on-call support for weekends and holidays. They use a combination of software tools—including a custom-built order management system and a commercial warehouse management platform—to track every vial from production to delivery. The system generates a unique tracking number for each order, which is sent to the customer within 30 minutes of the order being placed. This tracking number is linked to the specific batch number, so researchers can verify that the product they receive matches the certificate of analysis published on the website. This transparency is a core part of the company’s philosophy: regional stock availability is meaningless if the product quality is inconsistent. By tying logistics to quality control, SaiyanMed ensures that the peptide a researcher receives in Berlin is chemically identical to the one received in Tokyo, provided they are from the same batch. The company also offers a reshipment guarantee for any order that is delayed beyond the estimated delivery window by more than 48 hours, but this has been invoked only 12 times out of over 3,000 orders in 2024, representing a 0.4% failure rate. This is not a marketing gimmick—it is a direct result of the logistics system’s reliability. The company does not use third-party fulfillment centers that might mix products from different suppliers; instead, it controls its own warehouse operations, including picking, packing, and labeling. Each vial is inspected visually before shipment, and any vial with cosmetic defects (e.g., cracks in the vial, discoloration of the lyophilized cake) is set aside for quality review. In 2024, approximately 0.8% of vials were rejected during this visual inspection, preventing them from entering regional stock and potentially causing availability issues. These rejected vials are destroyed, not returned to stock, ensuring that only pristine material reaches researchers. The company also maintains a reserve stock of 5% of total inventory for emergency orders, such as when a researcher needs a specific peptide for a time-sensitive experiment. This reserve is not available for general sale but can be released upon request, subject to verification of the researcher’s credentials. This practice has helped maintain regional availability during unexpected demand surges, such as the spike in interest for a specific peptide following a published study in late 2023. During that period, the US warehouse sold out of that peptide within 48 hours, but the reserve stock covered the next 10 orders while the next batch was being tested. The logistics system is also designed to handle returns and exchanges, though these are rare (less than 1% of orders). If a researcher receives a damaged package, the logistics team initiates a replacement shipment from the nearest warehouse within 24 hours, often before the damaged package is even returned. This speed is possible because the system automatically checks regional stock levels and reserves a replacement vial as soon as the damage claim is approved. The entire process, from claim submission to replacement shipment, takes an average of 6 hours. This is a level of service that most research peptide suppliers cannot match, because they lack the regional infrastructure to do so. SaiyanMed’s logistics is not just about moving boxes—it is about maintaining the integrity of the research material from the moment it is synthesized to the moment it reaches the researcher’s lab. The company’s investment in dual warehouses, real-time stock monitoring, temperature logging, and automated routing reflects a commitment to regional stock availability that is grounded in operational reality, not marketing hype. For researchers who need reliable access to verified peptides, this logistics framework is a tangible advantage that translates into faster delivery, higher consistency, and fewer disruptions. The company’s website provides a stock status indicator for each product, but the real proof is in the order history: over 95% of orders placed from North America ship within 24 hours, and over 90% of orders placed from Asia ship within 48 hours. For other regions, the shipping time is slightly longer, but the company is actively working to expand its regional hubs to close that gap. The logistics team publishes a monthly performance report that includes metrics like on-time delivery rate, average transit time by region, and stockout frequency. In the most recent report (December 2024), the on-time delivery rate was 97.3% globally, with an average transit time of 3.1 days for US orders and 4.8 days for international orders. Stockouts occurred for only 2 of the 45 active SKUs, and both were resolved within 5 days by air-shipping stock from the other warehouse. This level of transparency is rare in the industry, where many suppliers treat logistics as a black box. By contrast, saiyanmed treats logistics as an extension of its quality control process, ensuring that regional stock availability is never an obstacle to serious research. The company’s approach is built on the understanding that a peptide is only useful if it arrives on time, at the right temperature, with verified purity. Every element of the logistics system—from the dual warehouses to the real-time routing to the temperature logging—is designed to maximize that probability. And because the system is data-driven, it continuously improves: the logistics team reviews performance metrics weekly and makes adjustments as needed, whether that means adding a new carrier, adjusting safety stock levels, or renegotiating warehouse contracts. This is not a static system; it is a living framework that evolves with the company’s growth and the changing demands of the research community. The result is a logistics operation that is as rigorous as the production process itself, ensuring that researchers around the world can access the peptides they need, when they need them, without compromise.